Charmacy Pharmaceutical Co., Ltd.

Informe acción SEHK:2289

Capitalización de mercado: HK$1.0b

Salud financiera de hoja de balance de Charmacy Pharmaceutical

Salud financiera controles de criterios 2/6

Charmacy Pharmaceutical tiene un patrimonio de accionistas total de CN¥592.2M y una deuda total de CN¥948.8M, lo que sitúa su ratio deuda-patrimonio en 160.2%. Sus activos y pasivos totales son CN¥3.3B y CN¥2.7B respectivamente. El BAIT de Charmacy Pharmaceutical es de CN¥129.4M, por lo que su ratio de cobertura de intereses es de 2.5. Tiene efectivo e inversiones a corto plazo que ascienden a CN¥417.4M.

Información clave

160.2%

Ratio deuda-patrimonio

CN¥948.84m

Deuda

Ratio de cobertura de intereses2.5x
EfectivoCN¥417.41m
PatrimonioCN¥592.15m
Total pasivoCN¥2.68b
Activos totalesCN¥3.27b

Actualizaciones recientes sobre salud financiera

Recent updates

There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

May 13
There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

Apr 24
There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jan 19
Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well

Oct 25
These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well

If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity

Sep 17
If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity

Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?

May 02
Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?

What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Mar 15
What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?

Feb 17
Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?

We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide

Jan 27
We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide

Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture

Jan 09
Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture

What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us

Dec 22
What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us

Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years

Nov 29
Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (CN¥2.8B) de 2289 superan a sus pasivos a corto plazo (CN¥2.6B).

Pasivo a largo plazo: Los activos a corto plazo de 2289 (CN¥2.8B) superan a sus pasivos a largo plazo (CN¥40.5M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de 2289 (89.7%) se considera alta.

Reducción de la deuda: El ratio deuda-patrimonio de 2289 ha crecido de 108.8% a 160.2% en los últimos 5 años.

Cobertura de la deuda: El flujo de caja operativo de 2289 es negativo, por lo que la deuda no está bien cubierta.

Cobertura de intereses: Los pagos de intereses de la deuda de 2289 no están bien cubiertos por el BAIT (2.5x cobertura).


Hoja de balance


Descubre empresas con salud financiera